The worldwide increase in multidrug-resistant bacteria has intensified into a significant public health emergency, with antibiotics proving ineffective against life-threatening infections. Bacteriophages, which are viruses that specifically target and eliminate bacteria, have emerged as a promising alternative. These minuscule entities eradicate bacteria by injecting their genetic material and lysing bacterial cells, providing a level of precision that is unparalleled by antibiotics while preserving beneficial microbial flora.
In the year 2016, a critically ill individual in the United States confronted an untreatable Acinetobacter baumannii infection subsequent to surgical intervention. After all antibiotic options were exhausted, researchers resorted to phage therapy, administering a mixture of phages directly at the infection site. Remarkably, the patient experienced recovery, marking this as one of the initial documented triumphs of phage therapy during a medical emergency. This incident sparked worldwide interest in reconsidering phages as feasible therapeutic agents.
Bacteriophages demonstrate an exceptional capacity for adaptation, evolving concurrently with bacterial species to overcome their resistance strategies. They exhibit remarkable efficacy against multidrug-resistant pathogens, including Pseudomonas aeruginosa and Klebsiella pneumoniae. Recent advancements facilitate synthetic alterations aimed at enhancing their therapeutic potential. The synergistic combination of phages with antibiotics has been shown to improve the successful elimination of bacterial infections. Global clinical trials have reported favorable results, notably a 2023 study published in Nature Medicine that underscored the efficacy of phage therapy in managing chronic Staphylococcus aureus infections.
Despite their promising potential, several challenges remain. Customizing bacteriophages to correspond with particular bacterial strains necessitates the implementation of rapid diagnostic methodologies. The production of scalable and individualized phage formulations continues to be intricate; however, innovations in sequencing technologies and artificial intelligence are working to mitigate these obstacles. In addition to their healthcare applications, bacteriophages also serve significant roles in agriculture by diminishing antibiotic-resistant strains within livestock and curbing their transmission to humans.
Bacteriophages present a viable solution for a post-antibiotic landscape, offering targeted, environmentally sustainable, and effective therapies against resistant pathogens. Although further investigation and regulatory endorsement are imperative, they constitute a formidable strategy in combatting the escalating challenge of antimicrobial resistance.
By: Fareeha, PhD Biosciences
Reference:
- → Dedrick, R. M., et al. (2019). Engineered bacteriophages for treatment of a patient with a disseminated Mycobacterium abscessus infection. Nature Medicine, 25(5), 730-733.
- → Schooley, R. T., et al. (2017). Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrobial Agents and Chemotherapy, 61(10), e00954-17.
- → Kortright, K. E., et al. (2019). Phage therapy: A renewed approach to combat antibiotic-resistant bacteria. Cell Host & Microbe, 25(2), 219-232.
- → Morrisette et al., (2020). Bacteriophage therapeutics: a primer for clinicians on phage‐antibiotic combinations. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 40(2), 153-168.
